Literature DB >> 183839

REM latency: a psychobiologic marker for primary depressive disease.

D J Kupfer.   

Abstract

Previous investigations have indicated that one of the most consistent EEG sleep findings in depressive patients has been a shortened REM latency. On the basis of these studies, we have concluded that with the exception of drug withdrawal states (such as CNS depressant or amphetamine withdrawal and narcolepsy) shortened REM latency points to a strong affective component in the patient's illness. Short REM latency has also been observed in patients suffering from schizo-affective illness as well as in certain schizophrenic patients who require tricyclic antidepressants in their management. Furthermore, this psychobiologic marker is a persistent, rather than a transient phenomenon, and can be observed over a period of several weeks unless a patient's condition becomes more favorable through clinical intervention. This present report indicates that short REM latency is found in virtually all primary depressive illness and is absent in secondary depression. Thus, REM latency appears to be a dependable, measurable marker for diagnosing primary depression, and we argue that the phenomenon is independent of age, drug effect and changes in other sleep parameters. It is expected that EEG sleep and motor measurements can yield further significant data and improve differential diagnosis in psychiatry, in much the same way that laboratory data support other medical specialities.

Entities:  

Mesh:

Year:  1976        PMID: 183839

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  42 in total

1.  Effect of the antidepressant Org 3770 on human sleep.

Authors:  G S Ruigt; B Kemp; C M Groenhout; H A Kamphuisen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Imipramine and EEG sleep in children with depressive symptoms.

Authors:  D J Kupfer; P Coble; J Kane; T Petti; C K Conners
Journal:  Psychopharmacology (Berl)       Date:  1979-01-31       Impact factor: 4.530

3.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

Review 4.  Sleep and mental disorders: A meta-analysis of polysomnographic research.

Authors:  Chiara Baglioni; Svetoslava Nanovska; Wolfram Regen; Kai Spiegelhalder; Bernd Feige; Christoph Nissen; Charles F Reynolds; Dieter Riemann
Journal:  Psychol Bull       Date:  2016-07-14       Impact factor: 17.737

Review 5.  Basic sleep and circadian science as building blocks for behavioral interventions: a translational approach for mood disorders.

Authors:  Lauren D Asarnow; Adriane M Soehner; Allison G Harvey
Journal:  Behav Neurosci       Date:  2014-04-28       Impact factor: 1.912

Review 6.  REM sleep abnormalities and psychiatry.

Authors:  J A Fleming
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

7.  Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression.

Authors:  Malika El Yacoubi; Saoussen Bouali; Daniela Popa; Laurent Naudon; Isabelle Leroux-Nicollet; Michel Hamon; Jean Costentin; Joëlle Adrien; Jean-Marie Vaugeois
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

8.  [Disturbances of slow-wave sleep and psychiatric disorders].

Authors:  J P Doerr; V Hirscher; D Riemann; U Voderholzer
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

9.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

10.  Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86.

Authors:  D Riemann; F Hohagen; M Bahro; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.